Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS
September 07, 2022 08:00 ET
|
Oncocyte Corporation
IRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
August 31, 2022 16:01 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Five-Year VA Contract for DetermaRx
August 30, 2022 16:27 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized...
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer
August 24, 2022 08:00 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Reports Second Quarter 2022 Financial Results
August 10, 2022 16:05 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Participate at Upcoming Investor Conferences
August 03, 2022 16:01 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022
August 01, 2022 05:00 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Announce Second Quarter 2022 Financial Results
July 27, 2022 16:01 ET
|
Oncocyte Corporation
IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business
July 13, 2022 08:00 ET
|
Oncocyte Corporation
Oncocyte enters $2B US transplant monitoring market with newly branded VitaGraft™ patented dd-cfDNA technology in two indications, Kidney and Liver Oncocyte initiates IVD Kit Development Process with...
Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022
July 06, 2022 08:00 ET
|
Oncocyte Corporation
Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the 2022 ASCO Annual Meeting DetermaIO may help to...